Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities

Public Health Relevance

The senior leadership supports the mission ofthe Cancer Institute of New Jersey (CINJ) as a National Cancer institute (NCI)-designated comprehensive cancer center to increase scientific depth and breadth in basic, clinical and public health sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-16W4
Application #
8728345
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-07-01
Project End
2017-02-28
Budget Start
2013-07-01
Budget End
2014-02-28
Support Year
16
Fiscal Year
2013
Total Cost
$31,250
Indirect Cost
$11,596
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Cannioto, Rikki A; LaMonte, Michael J; Kelemen, Linda E et al. (2016) Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer 115:95-101
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Stapleton, Jerod L; Hillhouse, Joel J; Turrisi, Rob et al. (2016) The Behavioral Addiction Indoor Tanning Screener (BAITS): An Evaluation of a Brief Measure of Behavioral Addictive Symptoms. Acta Derm Venereol 96:552-3
Manne, Sharon; Hudson, Shawna V; Baredes, Soly et al. (2016) Survivorship care experiences, information, and support needs of patients with oral and oropharyngeal cancer. Head Neck 38 Suppl 1:E1935-46
Viola, Adrienne S; Giovenco, Daniel P; Miller Lo, Erin J et al. (2016) A cigar by any other name would taste as sweet. Tob Control 25:605-6
Qin, Bo; Moorman, Patricia G; Alberg, Anthony J et al. (2016) Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. Br J Nutr 115:694-702
Zhang, Cen; Liu, Juan; Huang, Grace et al. (2016) Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev 30:1956-70
Pan, Ji-An; Sun, Yu; Jiang, Ya-Ping et al. (2016) TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis. Mol Cell 61:720-33
Stapleton, Jerod L; Tatum, Kristina L; Devine, Katie A et al. (2016) Skin Cancer Surveillance Behaviors Among Childhood Cancer Survivors. Pediatr Blood Cancer 63:554-7
Spencer, Kristen R; Mehnert, Janice M (2016) Importance of including patients with comorbidities in clinical trials. Lancet Oncol 17:17-8

Showing the most recent 10 out of 623 publications